CVRx (CVRX)

Executive Summary

CVRx is a Minneapolis-based medical device company pioneering neuromodulation therapy for chronic cardiovascular diseases, with its lead product Barostim™—an implantable device that activates the carotid baroreflex to improve symptoms and quality of life in heart failure patients. Barostim is FDA-approved and has shown promise in reducing hospitalizations and enhancing functional capacity. The company addresses a large unmet need in the estimated 6 million U.S. heart failure patients, many of whom are not adequately managed by pharmacotherapy alone. CVRx is transitioning from early commercialization to a growth phase, focusing on expanding clinical evidence, physician adoption, and reimbursement coverage. With a market cap around $180 million and a novel technology platform, the company represents a high-risk, high-reward opportunity in the cardiovascular device space.

Upcoming Catalysts (preview)

• 2025 Q4BeAT-HF Pivotal Trial Results75% success
• 2026 Q2CMS National Coverage Determination (NCD) for Barostim60% success
• 2026 Q4Potential Hypertension Indication Expansion40% success